Abdullah Karadağ

Abdullah Karadağ

Auto-generated profile, based on publicly available information

Abdullah Karadağ

Molecular Oncology Laboratory, Medical Biotechnology Research Group, VPLS, TÜBİTAK Marmara Research Center, Kocaeli, Turkiye

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2000 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
AKAbdullah Karadag
Abdullah Karadag
ASAndrew M. Scutt
Andrew M. Scutt
PCPeter I. Croucher
Peter I. Croucher
Multiple myeloma is associated with the development of osteolytic bone disease characterized by a disruption to normal bone resorption and bone formation. Although studies have shown that myeloma cells produce factors that promote bone resorption little data are available examining the mechanism of decreased bone formation or the factors that mediate this effect. In the present study we describe a novel in vitro coculture system in which to investigate the effect of myeloma cells on osteoblast recruitment and differentiation. Under appropriate conditions mesenchymal stem cells were shown to differentiate into colonies of cells, a proportion of which show characteristics of osteoblasts, in that they express alkaline phosphatase activity and stain positively for collagen and calcium. The addition of the human myeloma cells JJN-3, RPMI-8226, or NCI-H929 to these cultures stimulated a significant increase in the total number of colonies (p < 0.005) and the proportion of osteoblastic colonies (p < 0.005). Media conditioned by these cells also were able to promote the formation of both total and osteoblastic colonies (p < 0.005). The addition of an antibody against the interleukin-6 receptor (IL-6R) blocked myeloma cell and myeloma cell-conditioned media induced osteoblast recruitment (p < 0.01). Furthermore, media conditioned by myeloma cells incubated with phorbol ester, which promotes IL-6R shedding, or a metalloproteinase inhibitor, which inhibits IL-6R shedding, were able to stimulate (p < 0.005) and inhibit osteoblast recruitment (p < 0.005), respectively. In addition, soluble IL-6R (sIL-6R) and IL-6 together, but not alone, were able to promote osteoblastic colony formation (p < 0.01). Taken together these data show that myeloma cells promote osteoblast recruitment by release of sIL-6R from myeloma cells.

1 January 2014 in Journal of Traffic and Logistics Engineering
Verified
Journal Article
Closed access
FGFatih Gündoğan
Fatih Gündoğan
ZKZekai Karagoz
Zekai Karagoz
NKNihat Kocyigit
Nihat Kocyigit
AKAbdullah Karadag
Abdullah Karadag
HCHalim Ceylan
Halim Ceylan
YMYetiş Şazi Murat
Yetiş Şazi Murat
Journal of Traffic and Logistics Engineering (JTLE)

26 June 2024 in TURKISH JOURNAL OF BIOLOGY
Verified
Journal Article
Open access
PDF file
DÇDi̇lEk Demi̇rCan Çeker
Di̇lEk Demi̇rCan Çeker
VBVolkan Baysungur
Volkan Baysungur
SESerdar Evman
Serdar Evman
IKIlker Kolbas
Ilker Kolbas
AGAbdurrahi̇m Gördebi̇l
Abdurrahi̇m Gördebi̇l
AKAbdullah Karadağ
Abdullah Karadağ
Background/aim: LUNGBANK was established as a pioneering biorepository dedicated to lung cancer. Designed for streamlined biospecimens handling, it employs high-volume technologies to secure high-quality samples. Fortified with robust data management, LUNGBANK efficiently integrates diverse datasets. This strategic infrastructure positions LUNGBANK as more than a biospecimens repository; it operates as a sophisticated platform for advanced lung cancer research, amplifying the potential for meaningful discoveries.Materials and methods: LUNGBANK is intricately designed to streamline the collection, transfer, storage, and processing of biospecimens, employing high-volume technologies to ensure the acquisition of high-quality biological specimens. The system is fortified with robust data management protocols, facilitating efficient integration of diverse datasets. This strategic infrastructure ensures that LUNGBANK not only serves as a repository of biospecimens but also operates as a sophisticated platform for advanced lung cancer research.Results: LUNGBANK plays an essential role in furnishing a rich collection of biospecimens essential for unraveling the molecules and mechanisms linked to lung cancer. Rigorous standard operating procedures guided the meticulous collection of biospecimens, subjecting them to stringent quality control measures before inclusion in the study. Moreover, LUNGBANK has proven valuable in the establishment of patient-derived systems. The incorporation of cutting-edge technologies guarantees the acquisition of top-tier data, thereby amplifying the likelihood of substantial breakthroughs in both contemporary translational research and traditional histological evaluations.Conclusion: The establishment of LUNGBANK marks a significant stride towards addressing the pressing need for effective diagnostic and therapeutic systems in lung cancer research. By facilitating the collection and analysis of high-quality biospecimens, LUNGBANK serves as a valuable resource for unraveling the molecular intricacies of lung cancer initiation and progression. This comprehensive system not only supports Project LUNGMARK but also contributes to the broader landscape of personalized medicine, tailoring interventions to the specific needs of lung cancer patients.

24 January 2024 in Research Square
Verified
Preprint
Open access
PDF file
DCDilek Ceker
Dilek Ceker
VBVolkan Baysungur
Volkan Baysungur
SESerdar Evman
Serdar Evman
IKIlker Kolbas
Ilker Kolbas
AGAbdurrahim Gordebil
Abdurrahim Gordebil
AKAbdullah Karadag
Abdullah Karadag
Background:In support of Project LUNGMARK, LUNGBANK was established as a pioneering biorepository dedicated to lung cancer. Designed for streamlined biospecimen handling, it employs high-volume technologies to secure high-quality samples. Fortified with robust data management, LUNGBANK efficiently integrates diverse datasets. This strategic infrastructure positions LUNGBANK as more than a biospecimen repository; it operates as a sophisticated platform for advanced lung cancer research, amplifying the potential for meaningful discoveries.Methods:In support of Project LUNGMARK, the establishment of LUNGBANK, a pioneering biorepository system dedicated to lung cancer, was undertaken. LUNGBANK is intricately designed to streamline the collection, transfer, storage, and processing of biospecimens, employing high-volume technologies to ensure the acquisition of high-quality biological specimens. The system is fortified with robust data management protocols, facilitating efficient integration of diverse datasets. This strategic infrastructure ensures that LUNGBANK not only serves as a repository of biospecimens but also operates as a sophisticated platform for advanced lung cancer research, enhancing the potential for meaningful discoveries in the field.Results:LUNGBANK, serving as a groundbreaking biorepository system, plays a pivotal role in furnishing a rich collection of biospecimens essential for unraveling the molecules and mechanisms linked to lung cancer. Rigorous standard operating procedures guided the meticulous collection of biospecimens, subjecting them to stringent quality control measures before inclusion in the study. Moreover, LUNGBANK has proven valuable in the establishment of patient-derived systems. The incorporation of cutting-edge technologies guarantees the acquisition of top-tier data, thereby amplifying the likelihood of substantial breakthroughs in both contemporary translational research and traditional histological evaluations.Conclusion:The establishment of LUNGBANK marks a significant stride towards addressing the pressing need for effective diagnostic and therapeutic systems in lung cancer research. By facilitating the collection and analysis of high-quality biospecimens, LUNGBANK serves as a valuable resource for unraveling the molecular intricacies of lung cancer initiation and progression. This comprehensive system not only supports Project LUNGMARK but also contributes to the broader landscape of personalized medicine, tailoring interventions to the specific needs of lung cancer patients.

6 April 2023
Verified
Book Chapter
Closed access
MHMehmet Haklıdır
Mehmet Haklıdır
SNSinem Nalbantoğlu
Sinem Nalbantoğlu
AKAbdullah Karadağ
Abdullah Karadağ
In the last half century, as a result of breakthroughs in molecular biology, incredible amounts of big data have been produced from a living organism at the genomic, transcriptomic, proteomic and metabolomic levels with the help of high-volume modern technologies. Despite the similar rapid developments in statistical science and information technologies, sufficient progress has not been made in revealing the mechanisms underlying diseases and developing effective treatment systems by analyzing big data with bioinformatic methods. In the near future, it is expected that healthcare services will completely transform into intelligent systems. It is envisaged that this transformation will come into play with a structure consisting of big data, artificial intelligence, integrative multiomics and P-medicine, in which systems biology is at the center. Obtaining this structure, although initially costly, will become more economical over time due to individualized applications. Because it will be possible for people to live healthier, possible risks can be determined in advance, and more effective preventive measures can be taken, and the resulting pathologies can be controlled more economically with treatment systems suitable for the patient’s biological infrastructure. With this study, we aim to draw attention to the possible constructions of the smart health system, which we will talk about more in the coming years, and to open a discussion about the dynamics and needs of the model. We will review the developments in artificial intelligence, which we expect to be one of the basic pillars of this system and which has developed rapidly in recent years, and their adaptations to the smart health system, with the lens of systems biology.

6 April 2023
Verified
Book Chapter
Closed access
GGGizem Gulfidan
Gizem Gulfidan
KAKAZIM ARGA
KAZIM ARGA
DÇDilek Demircan Çeker
Dilek Demircan Çeker
AKAbdullah Karadağ
Abdullah Karadağ
The central dogma (basic assumption) of molecular biology is the assumption of the process of coding DNA, which contains the genetic material, transferring information to RNA and regulating protein synthesis according to the instructions in the code. Later, the concept of metabolites, i.e. products formed as a result of metabolic processes, was added when proteins begin to function by folding into active structures. In short, by adding the suffix -omic, the concepts that study these structures are derived. These are genomics, transcriptomics, proteomics, and metabolomics, respectively. However, later developments introduced the term “epi” into the literature, which plays a regulatory role without altering DNA, RNA, or protein sequences and is mostly dependent on environmental factors: Epigenomics, Epitranscriptomics, and Epiproteomics. The changes in these structures during normal and pathological processes have led to the acquisition of large amounts of data using high-throughput technologies. However, high performance information systems for analysis have not been able to be developed at the same pace. Information from a single omics analysis may not fully reflect the biological and clinical picture. Multi-omics data from multiple platforms, however, may offer significant potential for understanding the mechanisms underlying complex diseases and other clinical problems. New approaches to analyzing this Big Data have emerged, and the concept of multi-omics has entered the literature in recent years, allowing us to understand how they are affected by signal changes. In the coming years, healthcare will evolve from traditional methods to a process of “smart healthcare.” The 3 pillars of this process will be integrated multi-omics analysis (integrative multi-omics), personalized medicine (P-medicine), and artificial intelligence (AI). In this study, the developments, methods, and tools in the field of multi-omics analysis that are just starting to be talked about will be summarized.